deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04384107

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants

Sponsor: Merck Sharp & Dohme LLC

Conditions Pneumococcal Infections
Interventions PCV13 V114
Updated 16 times since 2020 Last updated: Jul 20, 2023 Started: Jul 1, 2020 Primary completion: Dec 1, 2021 Completion: Dec 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pneumococcal Infections and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Aug 2023 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Jun 2022 — Dec 2022 [monthly]

    Completed PHASE3

  2. Jan 2022 — Jun 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  9. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE3

  11. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Fujieda, Japan , Fukui, Japan , Fukuoka, Japan , Funabashi, Japan , Hioki, Japan , Ina, Japan , Isumi, Japan , Izumisano, Japan , Kasuga, Japan , Kasugai, Japan and 25 more locations